Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U9IB
|
||||
| Former ID |
DIB019811
|
||||
| Drug Name |
eledoisin
|
||||
| Synonyms |
ELD 950; eledone peptide; ELD-950
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C54H85N13O15S
|
||||
| InChI |
InChI=1S/C54H85N13O15S/c1-7-30(4)44(53(81)57-27-42(70)60-36(24-29(2)3)49(77)61-33(45(56)73)20-23-83-6)66-50(78)37(25-32-14-9-8-10-15-32)63-46(74)31(5)58-48(76)38(26-43(71)72)64-47(75)34(16-11-12-21-55)62-51(79)39(28-68)65-52(80)40-17-13-22-67(40)54(82)35-18-19-41(69)59-35/h8-10,14-15,29-31,33-40,44,68H,7,11-13,16-28,55H2,1-6H3,(H2,56,73)(H,57,81)(H,58,76)(H,59,69)(H,60,70)(H,61,77)(H,62,79)(H,63,74)(H,64,75)(H,65,80)(H,66,78)(H,71,72)/t30-,31-,33-,34-,35-,36-,37-,38-,39-,40-,44-/m0/s1
|
||||
| InChIKey |
AYLPVIWBPZMVSH-FCKMLYJASA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Substance-P receptor | Target Info | Agonist | [2] | |
| Nigral tachykinin NK(3) receptor | Target Info | Agonist | [3] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Measleshsa04020:Calcium signaling pathway | |||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| Reactome | G alpha (q) signalling eventsR-HSA-416476:G alpha (q) signalling events | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Spinal Cord Injury | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP2664:Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2086). | ||||
| REF 2 | The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J BiolChem. 1996 Aug 23;271(34):20250-7. | ||||
| REF 3 | Molecular characterisation, expression and localisation of human neurokinin-3 receptor. FEBS Lett. 1992 Mar 24;299(1):90-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.